Risankizumab is a Safe and Effective Long-Term Treatment for Plaque Psoriasis - Dermatology Advisor
Risankizumab is safe and effective for the long-term treatment of moderate-to-severe plaque psoriasis, according to study findings published in the Journal of the European Academy & Venereology . Researchers previously demonstrated the efficacy and safety of risankizumab for the treatment of moderate to severe plaque psoriasis over a 52-week period in 2 phase 3 UltiMMa-1/2 studies (ClinicalTrials.gov identifier: NCT02684370/ NCT02684357). However, data regarding the efficacy of risankizumab beyond 52 weeks are limited. Therefore, researchers conducted a phase 3 open-label extension study (LIMMitless; ClinicalTrials.gov identifier: NCT03047395) to evaluate the long-term efficacy of risankizumab for the treatment of psoriasis and its disease manifestation subtypes: nail, scalp, and palmoplantar psoriasis. Included patients (N=525) completed the UltiMMa-1/2 studies and subsequently enrolled in the LIMMitless study. Adults with moderate to severe plaque psoriasis we